(RTTNews) - Inspire Medical Systems, Inc. (INSP) announced on Friday that it has obtained FDA approval for Inspire V therapy system, its next generation Inspire neurostimulation system, for moderate to severe obstructive sleep apnea.
The Inspire V therapy system features the next generation neurostimulator, a Bluetooth-enabled patient remote, and a physician programmer.
The company stated that it intends to initiate a soft launch in late 2024, followed by a full launch in 2025 in the U.S. market.
In pre-market activity on the NYSE, the shares are trading at $137.90, up 4.97%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
